Alta Partners — Full Portfolio

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.

BiotechHealthtechCarlsbad, US

Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)Alan Fuhrman(Executive Officer)

BoardRobert More(Director)Nina Kjellson(Director)in

Co-investorsBioBritNextech InvestCanaan Partners

Nasdaq-listed clinical-stage immunology company in San Francisco developing hepatitis B/D antivirals and licensed T-cell engagers.

BiotechSan Francisco, US

Herbert Virgin(Executive Officer)Howard Horn(Executive Officer)Robert More(Director)Thomas Daniel(Director)Dipchand Nishar(Director)Robert Perez(Director)

Co-investorsARCH Venture Partners

CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.

BiotechHealthtech

Anthony Fordin

Co-investorsLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardJohn McKearn(Director)inPeter Moldt(Director)

Board seatDan JanneyFarah Champsi· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapitalRoche Venture Fund

Berkeley, US

Peter Calthorpe(Executive Officer, Director)

Board seatGarrett Gruener· per SEC Form D · $2M raise · filed Jul 2019

HealthtechPalo Alto, US

MARCEE M. MARONEY(Executive Officer)DAVID GRAVETT(Executive Officer)T. MICHAEL WHITE(Executive Officer)HAYLEY LEWIS(Executive Officer)DAVID M. RENZI(Executive Officer, Director)STEVEN BASTA(Director)

Board seatGuy Nohra· per SEC Form D · $4M raise · filed Mar 2015

Developing in vivo CAR-T cell therapies for cancer treatment

Cambridge, US

Board seatBob More· per SEC Form D

Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.

BiotechHealthtechMedical DevicesPittsburgh, US

Suma M. Krishnan(Director)Krish S. Krishnan(Chairman & CEO)Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)

Board seatDan Janney· per SEC Form D · $11.3M raise · filed Aug 2017

Co-investorsAvoro Capital AdvisorsFrazier Life Sciences

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)

BoardAleks Radovic-Moreno(Director)in

Board seatDan Janney· per SEC Form D

Co-investorsLongwood FundMission BiocapitalDolby Family VenturesForbionService Provider Capital

Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units.

BiotechHealthtechMedical DevicesCity Of Industry, US

Scott Elster(Executive Officer, Director)John M. Shields(Executive Officer)

BoardFrank Foster(Director)Martin Sutter(Director)David Brailer(Director)

Board seatDan Janney· per SEC Form D

Co-investorsAisling CapitalEssex Woodlands Healthcare PartnersFrontier Venture CapitalPROOF

Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Hugo Peris(Founder & CEO)Eugene de Juan(Executive Officer, Director)Lawrence Fritz(Director)

BoardWARREN THALER(Director)JEAN-FREDERIC PAULSEN(Director)

Board seatGuy Nohra· per SEC Form D · $10.9M raise · filed Feb 2023

Co-investorsCatalio Capital Management

USGI Medical develops endoluminal surgical technologies, including a shape-lockable flexible endoscopic platform (TransPort), endoluminal suturing tools, and expandable suture anchors, for incision-free, minimally invasive gastrointestinal procedures.

HardwareHealthtechMedical DevicesSan Clemente, US

Tracy Maahs(Executive Officer)Scott Moonly(Executive Officer, Director)John Cox(Executive Officer)

BoardMike Chuisano(Director)George Abi-Chahine(Director)

Board seatGuy Nohra· per SEC Form D · $4M raise · filed Jun 2019

HealthtechSan Clemente, US

Jeff Swiecki(Executive Officer)Earl R. Fender(Executive Officer, Director)Robert Reitzler(Executive Officer)Jeffrey A. Swiecki(Executive Officer)Scott C. Lynch(Executive Officer)Jeffrey A. Swiecke(Executive Officer)

Board seatGuy Nohra· per SEC Form D · $5M raise · filed Jul 2015

Co-investorsH.I.G. CapitalH.I.G. HealthBridge Partners

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)

Co-investorsAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)Sofinnova Ventures

BiotechCambridge, US

Tina Liu(Executive Officer, Director)David Cordo(Executive Officer)Erica Whittaker(Director)Steve Gillis(Director)

BoardBob More(Director)

Co-investorsARCH Venture Partners

Amplitude Therapeutics is a biotechnology company developing RNA-based medicines.

Biotech

Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.

Enterprise SoftwareFintechSaaS

Co-investorsAcies InvestmentsAloft VCAmity VenturesArtis VenturesAsymmetric Capital PartnersAt One Ventures+21 more

Co-investorsARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to CuresAtlas Venture+6 more

Co-investorsLongwood Fund

Boston, US

Dan Adams(Executive Officer, Director)

BoardPete Hudson(Director)inBruce Herzfelder(Director)Mark Prather(Director)

Bioventus develops orthobiologics and pain treatment products for orthopedic care, offering therapies such as the StimRouter neurostimulation device for chronic peripheral nerve pain.

BiotechHealthtechMedical Devices

Co-investorsAmpersandEssex Woodlands Healthcare Partners

Developed pharmaceuticals for B-cell cancers and immune diseases; acquired by MedImmune for up to $175M.

Co-investorsLatterell Venture Partners

Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.

BiotechHealthtechMedical DevicesDurham, US

Mike Sherman(Chief Executive Officer and President)Ronald C. Renaud, Jr(Director)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)

Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersFrazier Life SciencesPappas CapitalSanderling Ventures

Received FDA approval for Tracleer to treat pulmonary arterial hypertension.

PartnerDan Janney· led

Co-investorsFrazier Life SciencesSofinnova Ventures

BiotechSan Carlos, US

Anthony P. Ford(Executive Officer, Director)Benjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)

BoardRon Hunt(Director)Loretta Tse, Ph.D.(Director)

Co-investorsNew Leaf Venture Partners

Received FDA approvals for the enlighten and Secret RF microneedling systems for skin conditions.

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)

Co-investorsAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more

DispatchHealth delivers in-home medical care and house call services, offering patients an alternative to emergency rooms and urgent care facilities for acute medical conditions.

Digital HealthHealthtechDenver, US

Dr. Mark Prather(Founder)Kevin Riddleberger(Founder)Dominic Bagnoli(Director)

BoardPete Hudson(Director)in

Co-investorsEcho Health VenturesOak HC/FTOptum VenturesQuesta CapitalSINEWAVE VENTURES

Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a small molecule multi-kinase inhibitor that co-targets master regulators of cancer to trigger programmed cell death.

BiotechHealthtech

eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.

BiotechDeep TechMedical Devices

Mike Curtis, Ph.D.(President & Chief Executive Officer)

Co-investorsAltium CapitalEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGeorge M. Church(Director)

Co-investorsARCH Venture PartnersCatalio Capital Management, LPKhosla VenturesOUP (Osage University Partners)b2ventureKendall Capital Partners

BiotechAnn Arbor, US

Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)

PartnerDan Janney· led

Co-investorsAisling CapitalArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersLongitude Capital+2 more

Received FDA approvals for Vazculep and Akovaz to treat anesthesia-related hypotension.

Received FDA approval for Vyndamax and Vyndaqel to treat ATTR-CM cardiomyopathy.

Free Market Health operates a care-driven marketplace platform for the specialty pharmacy ecosystem.

B2B MarketplacesHealthtechSaaSPittsburgh, US

Joe Cardosi(Founder)in

Co-investorsQuesta Capital

Harbor provides electronic data capture (EDC) software for clinical trial teams, designed to reduce data entry time and enable remote monitoring to improve data quality and accelerate trial timelines.

HealthtechMedical DevicesSaaSSan Francisco, US

Albert Cai(Founder)inNathan H. Leung(Founder)in

Co-investorsY Combinator8VCDFOGeneral Catalyst

Harbor Plan provides automation software for independent professionals to manage their practices.

AI & Machine LearningFintechSaaSSales TechSan Francisco, US

Clinton A.(Managing Director)inRob Carrington(Head of Engineering)in

Co-investorsTechstarsTinySeed8VCDFOGeneral Catalyst

Crypto & Web3Enterprise SoftwareFintechSioux Falls, US

Co-investorsAndreessen HorowitzFuture Perfect VenturesKindred VenturesPantera Capital8VCDFO+2 more

Harbor builds an AI-powered baby monitor that provides real-time custom alerts and sleep insights, and operates with or without WiFi.

AI & Machine LearningConsumerHardware

Co-investorsCarnrite Ventures8VCDFOGeneral CatalystTrust Ventures

Harbor Health is a healthcare provider and insurance company operating clinics across Texas that offers primary care, specialty care, and health coaching alongside integrated insurance coverage.

HealthtechInsurTechAustin, US

Sterling Claiborne Johnston(Chief Medical Officer)Jeffrey Fisher(Chief Financial Officer)Eric Scott(Vice President)inKara Rios(Chief Financial Officer)

BoardPete Hudson(Director)inAnthony Miller(Director)in

Co-investors8VCHealth2047 Capital Partners LLCLemhi VenturesMartin VenturesBreyer CapitalCubit Capital+2 more

Oncology company that received FDA approval for Campath to treat B-cell chronic lymphocytic leukemia.

PartnerDan Janney· led

Pharma company acquired by Roche; received FDA approval for Esbriet to treat idiopathic pulmonary fibrosis.

Kelonia is a biotechnology company developing next-generation genetic medicines, with a focus on cell and gene therapy programs including in vivo approaches and oncology applications.

BiotechHealthtech

Kevin Friedman(Founder & Chief Executive Officer)in

Co-investorsHorizons Ventures

Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer.

BiotechHealthtechSanta Monica, US

Arie S. Belldegrun(Executive Officer, Director)Margo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)Marc Better(Executive Officer)Rizwana Sproule(Executive Officer)

BoardJoshua A. Kazam(Director)

Co-investorsPontifax Venture Capital

Biosciences company acquired by Bristol-Myers Squibb.

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)

Co-investorsCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value FundCatalio Capital Management+2 more

mBrace Therapeutics is a therapeutics company focused on drug development, led by executives with backgrounds in oncology and pharmaceutical business development.

BiotechHealthtech

Jay(Executive (former VP, Head of BD&A at AbbVie))

South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.

Daly City, US

Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)

BoardElizabeth Stanley(Director)

Co-investorsCerity Partners Ventures5AM VenturesDCVC Bio

Digital HealthHealthtechWellness & Fitness

PatientsLikeMe operates an online platform where patients track their conditions, treatments, and symptoms and connect with others who share similar health experiences.

Digital HealthHealthtechSocialCambridge, US

Philippe Amouyal(Director)Jonathan White(Director)Justin Barstein(Director)Martin Coulter(Executive Officer, Director)Jay M. Tenenbaum(Director)James Heywood(Director)

Co-investorsOptum Ventures

Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.

Co-investorsARCH Venture PartnersLAVSequoia Capital

Received FDA approval for Elocta to treat Hemophilia A.

Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions to help people navigate the healthcare system and access on-demand care.

AI & Machine LearningDigital HealthHealthtech

Co-investorsThreshold VenturesAlly Bridge GroupGeneral CatalystGeodesic CapitalHuman CapitalKinnevik+2 more

Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions into a single member experience, helping people navigate the healthcare system and access on-demand care.

AI & Machine LearningDigital HealthHealthtechDenver, US

Co-investors7wire VenturesCorewell Health VenturesGeneral CatalystGeodesic CapitalGreatPoint VenturesHuman Capital+5 more

Pharmaceutical company acquired by Daiichi Sankyo.

United Musculoskeletal Partners is a physician-owned shared services organization that partners with musculoskeletal (MSK) physician practices, providing management services such as financial analytics, compliance, procurement, and value-based care support while practices retain clinical autonomy.

Digital HealthHealthtech

Co-investorsWCAS

Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.

AI & Machine LearningBiotechDigital HealthNew York, US

Kaja Wasik(Executive Officer, Director)Andrew Farnum(Chief Executive Officer)Stephane Castel(Co-Founder, Chief Scientific & Technology Officer)inCraig Basson(Chief Medical Officer, President of R&D)Holly Vance(Chief Operating Officer)

BoardJulie Sunderland(Director)

Co-investorsGeneral CatalystLux CapitalSoftBank Vision FundDimension Capital

Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.

AI & Machine LearningBiotechDigital HealthMedical Devices

Marianne De Backer(CEO)

Co-investorsARCH Venture PartnersSoftBank Vision Fund8VCSoftBank Group